Results Preview: Diovan loss will hurt Novartis in ‘a year of two halves’
This article was originally published in Scrip
Executive Summary
As investors settle in to a 'post-Diovan' Novartis, it is likely that the company's full-year 2012 results, due 23 January, will be well-received despite the lower sales.